Kyowa Kirin signs exclusive Poteligeo distribution deal with Knight Therapeutics in Latin America

BRAZIL — Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics to expand access to Poteligeo (mogamulizumab) in selected Latin American markets.

The agreement, announced on September 29, 2026, covers Brazil, Argentina, Mexico and Colombia, where Knight will manage regulatory submissions and commercial distribution of the therapy for patients with cutaneous T-cell lymphoma (CTCL).

Agreement expands Latin American commercial reach

Under the agreement, Knight Therapeutics will hold exclusive distribution rights for mogamulizumab in the four markets and will be responsible for obtaining the necessary regulatory approvals before commercialization.

The partnership represents Kyowa Kirin’s first commercial arrangement for mogamulizumab in Latin America.

The deal gives Kyowa Kirin access to Knight’s pan-American commercial infrastructure while allowing Knight to add a targeted oncology therapy to its portfolio.

For the four markets, regulatory approval and market access activities will determine when the medicine becomes commercially available.

Kyowa Kirin Emerging Growth Markets Cluster General Manager Céline Rhême said CTCL is more common in Latin America than is widely recognised and that further work is needed to identify unmet needs and improve patient outcomes.

 She added that the partnership with Knight could help expand patient access to treatment in the region.

Poteligeo targets malignant T cells

Poteligeo is a humanised monoclonal antibody that targets CC chemokine receptor 4 (CCR4), a protein frequently expressed on malignant T cells in CTCL.

The therapy uses Kyowa Kirin’s proprietary POTELLIGENT technology, which enhances antibody-dependent cellular cytotoxicity, an immune mechanism that helps destroy targeted cancer cells.

The medicine is authorised in several markets for adults with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.

MF and SS are the two most common subtypes of CTCL, a rare form of non-Hodgkin lymphoma.

CTCL develops when malignant T lymphocytes accumulate in the skin and, depending on disease stage, can also affect the blood, lymph nodes and internal organs.

 Early symptoms may include red patches or plaques that resemble common inflammatory skin conditions such as eczema or psoriasis, which can complicate diagnosis.

In more advanced disease, patients can develop tumours or widespread skin redness known as erythroderma.

Kyowa Kirin continues rare disease expansion

The Latin American agreement follows other recent regulatory activity involving Kyowa Kirin’s rare disease portfolio.

 In July 2026, the European Commission approved an expanded indication for Crysvita (burosumab) to treat infants aged one month to one year with X-linked hypophosphataemia (XLH) across the European Union and European Economic Area.

The decision followed a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in April 2026.

The expanded indication enables the use of burosumab in younger patients with XLH, a rare genetic disorder characterised by phosphate wasting and impaired bone mineralisation.

For mogamulizumab, the new Latin American partnership assigns responsibility for regulatory filings and commercialisation to a regional pharmaceutical company, creating a defined route to introduce the therapy in Brazil, Argentina, Mexico, and Colombia.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on LinkedIn for updates.